ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1920

Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment

Andrea Rubbert Roth1, Scott Tschuppert2, Thomas Neumann2, Ulf Benecke3, Ian Pirker3 and Johannes von Kempis3, 1Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 2Kantonsspital St Gallen, St.Gallen, Switzerland, 3Kantonspital St Gallen, St. Gallen, Switzerland

Meeting: ACR Convergence 2020

Keywords: giant cell arteritis, glucocorticoids, Interleukins

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual affection is still limited. We sought to study the outcome of patients with GCA and visual affection treated with TCZ.

Methods: This retrospective analysis was performed on all patients with GCA and visual disturbances consecutively recruited between April 2013 and May 2020 who underwent treatment with tocilizumab in addition to corticosteroids.

Results: 19 GCA patients (14 women, 5 male) with a mean age of 73.4 + 10 yrs at GCA diagnosis and 28 affected eyes were treated with tocilizumab in addition to corticosteroids.

4/19 patients presented with visual disturbances  on oral prednisone and 2/19 patients were on csDMARDs (leflunomide, MTX) for polymyalgia. 2 patients experienced unilateral blindness while receiving iv pulse corticosteroids. AAION was diagnosed in 23/28 eyes, PION in 1/28 eyes and occlusion of the central retinal artery in 4/28 eyes. Loss of vision below 0.1 BCVA  occurred in 12/28 eyes. Non patients had bilateral blindness at baseline. 5/28 eyes were affected by sectorial anopsia, impaired vision was reported in 11/28 eyes. 17 patients were treated with TCZ iv 8mg/kg every 4 weeks, 2 patients received TCZ sc at 162mg every 2 weeks.

All patients with visual symptoms received intravenous steroid boluses, followed by predni-sone 1mg/kg/day with subsequent tapering.

Mean disease duration before initiation of tocilizumab was 1.8 + 1.7 months. 11/19 patients started with TCZ within 6 weeks after diagnosis of GCA, in 3 patients TCZ was started because of refractory and/or relapsed disease.

Mean duration of TCZ therapy was 18.9 + 11.5 months. 14/19 patients were able to stop steroids (GC) after a mean duration of 16.7 + 14.8 months and have been steroid-free for an average time of 15 + 10.4 months. In addition to cessation of GC, 8 patients have discon-tinued TCZ, 2 patients relapsed after 11 and 14 months. At present, 6 patients remain drug-free for 3 to 28 months (16 + 11 months). None of the 12 eyes with vision < 0.1 BCVA recovered, but no new vision disturbances occurred during TCZ or after cessation of either TCZ or GC.  

Two patients died during follow-up for reasons unrelated to GCA or TCZ. Overall tolerability of TCZ was good, complications were predominantly vascular (2 patients with VTE, one NSTEMI, one stroke and the development of an aortic aneurysm).

Conclusion: Inhibition of IL-6 with TCZ represents a valuable  treatment option to prevent deterioration of visual complications in GCA patients with initial visual impairment.


Disclosure: A. Rubbert Roth, AbbVie, 1, Bristol-Myers Squibb, 1, Chugai Pharma, 1, 2, Eli Lilly, 1, 2, Hexal, 1, Novartis, 1, Sanofi, 1, 2, Roche, 1, 2, Pfizer, 1, Merck Sharp & Dohme (MSD), 1, Janssen, 1; S. Tschuppert, None; T. Neumann, None; U. Benecke, None; I. Pirker, None; J. von Kempis, None.

To cite this abstract in AMA style:

Rubbert Roth A, Tschuppert S, Neumann T, Benecke U, Pirker I, von Kempis J. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arteritis-and-visual-impairment/. Accessed January 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-tocilizumab-in-patients-with-giant-cell-arteritis-and-visual-impairment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.